You are here: Industry Insights > ARDS

News List

USFDA approves IND application from Reven Pharma for Rejuveinix to treat COVID-19 expresspharma
October 26, 2020
RJX is an IV formulation being developed for treatment of inflammatory disorders, including COVID-19 patients with viral sepsis, multi-system inflammation, cytokine release syndrome, shock, ARDS and multi-organ failure.
Novellus Licenses Induced Mesenchymal Stem Cells to NoveCite for COVID-19 Related ARDS americanpharmaceuticalreview
October 19, 2020
Novellus Therapeutics has licensed its induced mesenchymal stem cells (iMSCs) on a worldwide basis to NoveCite, a newly formed subsidiary of Citius Pharmaceuticals.
NoveCite to develop stem cell therapies for COVID-19 related respiratory distress europeanpharmaceuticalreview
October 10, 2020
NoveCite has an exclusive licence to develop and commercialise mesenchymal stem cell therapies to treat acute respiratory conditions such as Acute Respiratory Distress Syndrome (ARDS).
FDA Grants IND, Approves Trial Protocol of Inhaled Ampion for COVID-19 americanpharmaceuticalreview
September 27, 2020
Ampio Pharmaceuticals announces the receipt of an Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA), allowing the Company to proceed with clinical trials for the use of Ampion as an inhalation therapy for respiratory ...
Seattle AVM Announces Second IND for AVM0703 for COVID-19, Influenza ARDS americanpharmaceuticalreview
September 23, 2020
AVM Biotechnology has received U.S. Food and Drug Administration (FDA) permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza ...
Direct Biologics Initiates Patient Enrollment in EXIT COVID-19 Clinical Trial ExoFlo americanpharmaceuticalreview
September 15, 2020
Direct Biologics announced the launch of EXIT COVID-19, their Phase II, multi-center clinical trial examining the use of ExoFlo™ extracellular vesicles to treat COVID-19 associated acute respiratory distress syndrome (ARDS).
Cartesian Initiates Trial of Cell Therapy for ARDS, COVID-19 americanpharmaceuticalreview
September 02, 2020
Cartesian Therapeutics has initiated a Phase 1/2 clinical trial of its lead RNA-engineered mesenchymal stem cell (MSC) therapy, Descartes-30, in patients with moderate-to-severe acute respiratory distress syndrome (ARDS), including that caused by COVID-19
FDA accepts Enzychem’s IND for trial of Covid-19 treatment candidate pharmaceutical-business-review
August 19, 2020
The US Food and Drug Administration (FDA) has accepted Enzychem Lifescience’s investigational new drug application (IND) to assess its EC-18 therapeutic candidate for the prevention of acute respiratory disease syndrome (ARDS) due to Covid-19 pneumonia.
Omeros reports positive results for Narsoplimab in treatment of Covid-19-associated ARDS pharmaceutical-business-review
August 13, 2020
Omeros Corporation reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2) ...
Orion Biotechnology Receives Funding to Develop OB-002 contractpharma
July 31, 2020
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company, is receiving advisory services and conditional funding from the National Research Council Industrial Research Assistance Program (NRC IRAP) to support the development of Orion’s ...

Previous page 1 2 3 4 5 6 7 Next page